By: IPP Bureau
Last updated : May 22, 2026 6:58 am
Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore
Aurobindo Pharma Limited reported a 5.6% year-on-year increase in consolidated revenue from operations to Rs. 8,853 crore for Q4 FY26, driven by broad-based growth across business segments, particularly Europe and Growth Markets.
Net profit for the quarter rose 2% YoY to Rs. 921 crore.
The company’s Europe business emerged as a standout performer, recording a 30.2% YoY rise in quarterly revenues to Rs. 2,795 crore (EUR 261 million), helping the region cross the €1 billion annual revenue milestone in FY26.
Growth Markets revenues increased 24.7% YoY to Rs. 980 crore, while ARV revenues grew 6.4% to Rs. 328 crore.
However, the US formulations business declined 13% YoY to Rs. 3,543 crore due to lower transient sales, though it still contributed 40% of consolidated revenues during the quarter.
For the full financial year FY26, consolidated revenue from operations increased 6.1% to Rs. 33,653 crore, while annual net profit stood at Rs. 3,503 crore. EBITDA before R&D came in at Rs. 8,340 crore with a margin of 24.8%.
R&D spend, including depreciation, stood at Rs. 400 crore during the quarter, accounting for 4.5% of revenues. The company also received final approval for nine ANDAs from the USFDA during Q4 FY26 and launched 12 products in the US market.
K. Nithyananda Reddy, Vice-Chairman and Managing Director of Aurobindo Pharma, said the company’s performance reflected the resilience of its business model, strong product portfolio, improved operational efficiencies, and disciplined execution.